Physician profile
Afshin S Javaherian
NPI 1396765673
$15,333.15
in general payments reported to CMS, 2019-2025
19 companies · $920 in 2025
The $920 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $179 · 2021: $444 · 2022: $11K · 2023: $1,394 · 2024: $424 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Long Term Medical Supply Or Device Loan: $353 · Debt Forgiveness: $295 · Travel and Lodging: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.88 |
| Long Term Medical Supply Or Device Loan | $352.90 |
| Debt Forgiveness | $295.00 |
| Travel and Lodging | $103.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $6,822.14 | 2022-2023 | Restrata Wound Matrix |
| Integra Lifesciences Corporation | $5,342.81 | 2021-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Acell, INC. | $1,030.94 | 2019-2020 | |
| Smith+Nephew, INC. | $523.85 | 2019-2024 | Grafix Pl |
| Medline Industries Lp | $464.89 | 2019-2022 | |
| Nvision Biomedical Technologies, INC. | $231.30 | 2023 | Foot and Ankle |
| Paratek Pharmaceuticals, INC. | $195.42 | 2022-2023 | Nuzyra |
| Amgen INC. | $186.62 | 2025 | Krystexxa |
| Bone Support INC. | $127.72 | 2024 | Ceramentbone Void Filler, Cerament G |
| Urgo Medical North America, LLC | $90.10 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Ani Pharmaceuticals, INC. | $83.21 | 2024-2025 | Purified Cortrophin Gel |
| Zimmer Biomet Holdings, INC. | $63.23 | 2020 | |
| Kerecis Limited | $62.80 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Mimedx Group, INC. | $22.87 | 2025 | |
| Orthofix Medical, INC. | $20.44 | 2025 | Physio-Stim |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $18.45 | 2023 | Seglentis |
| Hikma Pharmaceuticals USA | $15.93 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.93 | 2021 | |
| Horizon Therapeutics Plc | $14.50 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshin Javaherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.